摘要
目的探讨加重期和稳定期COPD患者在YKIA0水平方面的差异。方法采用ELISA法检测2013年1月～2014年12月在我所住院的COPD加重期（AECOPD）的患者60例，COPD稳定期的患者59例及我所体检中心正常患者（对照组）50例血清中YKL-40的表达水平。分析COPD患者血清中YKL-40水平与COPD发病危险因素的相关性。结果实验结果显示，在对照组、COPD组和AECOPD组血清中YKL-40水平比较中，差异有统计学意义（P〈0．01），AECOPD组和COPD组血清中YKL-40水平比较显示，差异有统计学意义（P〈0．01）；AECOPD组血清中YKL-40水平比COPD组血清中的YKL-40水平高，差异有统计学意义（P〈0．01）。AECOPD组患者血清YKL-40含量与FEVI／FVC呈负相关（r=-0．605，P〈0．001），与FEV1％呈负相关（相关系数r=-0．525，P=0．003）。COPD组患者血清YKL-40含量与FEVI／FVC呈负相关（r=-0．601，P〈0．001），与FEVI％呈负相关（r=-0．466，P=0．009）。结论COPD患者患病不同时期体内YKL40水平不一，对于临床后续治疗和相关药物的使用具有指导意义，值得深入研究。
Objective To explore the YKL40 level change at exacerbation and stable stage of COPD patients. Methods ELISA method was used to detect the expression levels of YKL40 in serum of 60 cases of exacerbation stage of COPD patients, 59 cases of stable stage of COPD patients and 50 cases of normal patients （control group） in our physical examination center, which were cured in our station from January 2013 to December 2014. The correlation between serum YKL-40 level and the risk factors of COPD in patients with COPD was analyzed. Results Experimental results showed that there were statistical differences on serum YKL-40 level comparison in the control group, COPD group and AECOPD group （P 〈 0.01）. Serum YKL-40 level comparison between AECOPD group and COPD group showed that the difference was statistically significant （P 〈 0.01）. Serum YKL-40 level of AECOPD group was higher than that of COPD group, and the difference was statistically significant （P 〈 0.01）. The level of serum YKL-40 of AECOPD group was negatively correlated with FEV1/FVC （r=-0.605, P 〈 0.001）, and it is negatively correlated with FEV1% （correlation coefficient r=-0.525, P=0.003）. The level of serum YKL-40 of COPD group was negatively correlated with FEV1/FVC （r=-0.601, P 〈 0.001）, and it is negatively correlated with FEV1% （r=-0.466, P=0.009）. Conclusion Levels of YKL40 of COPD patients is different in different periods of time. It has guiding significance for clinical follow up treatment and the use of related drugs. It is worth in-depth study.
出处
《中国医药科学》
2016年第15期136-139,共4页
China Medicine And Pharmacy
基金
广东省肇庆市科技创新计划项目(2014E1113)
